Search Result for : Drug Price Control Order

The Dollar Business Bureau Indian Pharma exports to the US may increase in 2017-18 despite pricing pressure and stiff competition. A report released by Care Ratings said that $50 billion worth of drugs are expected to become 'off-patent' in the current year giving hope to the Indian Pharma export market. "The pharma export volumes from India to US, however, are expected to rise. This will be backed by about $55 billion expected sales gain to generics drugs on account of branded drugs going off patent during 2017-19 which will create an opportunity for CRAMS segment. We expect growth rate for CRAMS (Contract Research and Manufacturing Services) to be higher compared to average growth rate of the industry. These factors are likely to support pharma exports from India," ...

Sneha Gilada The pharma bigwigs, after the government recently imposed a cap on stent prices, are in for another rough ride as PM Modi seeks to make prescription of cheap generic drugs binding on doctors. Speaking at the inauguration ceremony of a charitable hospital in Surat on April 17, Narendra Modi vowed to take on the mantle of making healthcare affordable to the Indian middle class and poor. In his speech, he averred that the health policy was being revamped after a gap of 15 years. The last time it was updated was back in 2002. The new health policy lays special emphasis on the pricing of drugs included in the National List of Essential Medicines (NLEM), along with the timely revision of the list. "Price control ...

PTI  In a major relief to patients, the government has reduced prices of coronary stents by up to 400 per cent, capping them at Rs 7,260 for bare metal ones and Rs 29,600 for the drug-eluting variety. The National Pharmaceutical Pricing Authority (NPPA) in a notification said in public interest, it has fixed the ceiling price of bare metal stents at 7,260 and that of drug-eluting stents and bioresorbable vascular scaffold (BVS)/biodegradable stents at Rs 29,600. A coronary stent is a tube-shaped device placed in the arteries that supply blood to the heart. It keeps the arteries open in the treatment of coronary heart diseases. The maximum retail cost of a stent currently ranges from Rs 25,000 to Rs 1.98 lakh. ...

 The Dollar Business Bureau The Union Ministry of Chemicals and Fertilizers, on Tuesday, informed that the Special Committee recommendations are being examined for formulating a ‘Policy for Promotion of Manufacturing of Bulk Drugs’. The Union Minister Ananth Kumar informed Lok Sabha that a special Committee, under the chairmanship of Secretary, Department of Health Research, has been constituted to check the issues pertaining to the Active Pharmaceutical Ingredients (API). The Committee will check the whole issues of APIs by identifying the APIs of critical importance and will then work out on a package of interventions and procedures to build domestic production capabilities and further examine the cost implications, the Minister added. The recommendations made by the Committee include the ...

The Dollar Business  “With NLEM (National List of Essential Medicine) 2015 and DPCO (Drug Price Control Order) 2016, more drugs are likely to come under price control but this will not affect the growth of the pharmaceutical industry. The growth trend will be much better as compared to the past,” said a highly placed source from the Organisation of Pharmaceutical Producers of India (OPPI). “In the past, the Pharmaceutical Industry was not well prepared to take the impact of NLEM 2011 and the subsequent DPCO 2013,” added the source. While NLEM is a list of medicines, prepared by the Ministry of Health and Family Welfare, which are essential in India, the DPCO is an order issued by the government under the essential commodities ...